Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001248374 | SCV001421856 | likely benign | Kleefstra syndrome 1 | 2023-06-27 | criteria provided, single submitter | clinical testing | |
New York Genome Center | RCV001248374 | SCV001761091 | uncertain significance | Kleefstra syndrome 1 | 2020-06-19 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002430051 | SCV002731375 | uncertain significance | Inborn genetic diseases | 2018-08-27 | criteria provided, single submitter | clinical testing | The p.H72Q variant (also known as c.216C>A), located in coding exon 3 of the EHMT1 gene, results from a C to A substitution at nucleotide position 216. The histidine at codon 72 is replaced by glutamine, an amino acid with highly similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |